Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update

Pharmaceutical Investing

Xenon Pharmaceuticals (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2017 and provided a corporate update. As quoted in the press release: Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, said, “In 2017, we concentrated our efforts on developing novel ion channel modulators to address …

Xenon Pharmaceuticals (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2017 and provided a corporate update.

As quoted in the press release:

Dr. Simon Pimstone, Xenon’s President and Chief Executive Officer, said, “In 2017, we concentrated our efforts on developing novel ion channel modulators to address central nervous system (CNS) disorders, and our product candidates are advancing as planned. We believe that XEN1101 and XEN901, our two proprietary epilepsy products that are currently in clinical development, have unique mechanisms of action and other attractive properties that could differentiate them from existing anti-epileptic drugs presently available to prescribing physicians.”

Click here to read the full press release.

candidates central nervous system clinical-stage biopharmaceutical clinical-stage biopharmaceutical company corporate update financial results product candidates Pharmaceutical Investing